Bone morphogenetic protein receptor type-1 (BMPR1) and Bone morphogenetic protein receptor type-2 (BMPR2) (BMPR1, BMPR2)

Bone morphogenetic protein receptor type-1 (BMPR1) and type-2 (BMPR2) are transmembrane serine/threonine kinase receptors that are essential components of the signaling pathway for bone morphogenetic proteins (BMPs), which are members of the transforming growth factor-beta (TGF-β) superfamily[1][3][4]. BMPR1 and BMPR2 form heteromeric complexes at the cell surface that transduce extracellular BMP ligand signals into the cell, regulating gene expression via the phosphorylation of SMAD transcription factors[1][3]. These receptors play crucial roles in a range of developmental and adult biological processes, including cell differentiation, bone and cartilage formation, apoptosis, and vascular development[1][3][4]. Mutations in BMPR1A or BMPR2 are implicated in several diseases, such as juvenile polyposis syndrome, pulmonary arterial hypertension, and various cancers[3]. While BMPR inhibitors are under development as potential therapeutics, modulation of this pathway poses safety risks due to the broad involvement of BMP signaling in tissue and organ homeostasis[3]. Note: The query “BMPR1/BMPR2” is ambiguous because it combines two distinct, though functionally related, receptors. Accurate annotation generally requires selection of either BMPR1 (specifically BMPR1A or BMPR1B) or BMPR2. For structured data or therapeutic applications, these should be treated as separate canonical entities, as each has unique genetic, functional, and clinical profiles[3]. Therefore, is_incorrect is marked “true”.

Other names

BMPR-IA (for BMPR1A, also known as Activin receptor-like kinase 3, ALK3)BMPR-IB (for BMPR1B, also known as ALK6)BMPRII (for BMPR2)Activin receptor-like kinases (ALKs; specifically ALK3, ALK6 for type I)Type I and Type II BMP receptor

Inhibition of serine/threonine kinase activity; Blockade of ligand binding and signal transduction through the BMP pathway